BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Jan 10, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Results

PSI-7977: Interim Phase IIb data

Interim data from 24 evaluable treatment-naive patients with HCV genotype 2 or 3 in the open-label arm of an ongoing, U.S. Phase IIb trial showed that 400 mg PSI-7977 plus standard of care (SOC; Pegasys peginterferon alfa-2a and ribavirin) for 12 weeks resulted in a 100% RVR rate. Additionally, HCV...

Read the full 240 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >